HS-201 (Solid Malignancies) - Clinical Trial
Email to Participate
jessica.a.morris@duke.edu
What is the Purpose of this Study?
We are doing this study to see how much of the study drug (an imaging agent called HS-201) is needed to mark cancer cells and help doctors to see cancer during and after surgery.
Solid Malignancies (cells with cancer)
Who Can Participate in the Study?
-Adults
-Diagnosis of a solid malignancy
-Planned surgical removal or biopsy of cancerous cells
Adults
What is Involved?
If you choose to join this study you will:
-Have the the study drug (HS-201) given into your vein the day before your surgery.
-Have a small amount of tissue taken out during your surgery
One month after your surgery you will:
-Have a physical exam
-Answer questions about how you are feeling after your surgery
-Give blood samples
Study Details
Full Title
A PHASE I STUDY OF HS-201, AN HSP90 INHIBITOR-LINKED VERTEPORFIN FOR DETECTION OF SOLID MALIGNANCIES
Principal Investigator
H. KimLyerly
Protocol Number
IRB:
PRO00102188
NCT:
NCT03906643
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov